Allergies Medicines Approved in the EU (EMA)

• 32medicines authorised in the EU (authorised now)

Each number has its full source under its own list below.

• 23Apr2026

  Rhapsido

  Active substance: remibrutinib

  EMEA/H/C/006313
• 12Feb2026

  Exdensur

  Active substance: depemokimab

  EMEA/H/C/006446
• 12Feb2025

  Nemluvio

  Active substance: nemolizumab

  EMEA/H/C/006149
• 22Aug2024

  Eurneffy

  Active substance: epinephrine

  EMEA/H/C/006139
• 16May2024

  Omlyclo

  Active substance: omalizumab

  EMEA/H/C/005958
• 16Nov2023

  Ebglyss

  Active substance: Lebrikizumab

  EMEA/H/C/005894
• 19Apr2023

  Opzelura

  Active substance: ruxolitinib

  EMEA/H/C/005843
• 19Sep2022

  Tezspire

  Active substance: tezepelumab

  EMEA/H/C/005588
• 9Dec2021

  Cibinqo

  Active substance: abrocitinib

  EMEA/H/C/005452
• 17Jun2021

  Adtralza

  EMEA/H/C/005255
• 17Dec2020

  Palforzia

  Active substance: defatted powder of Arachis hypogaea L., semen (peanuts)

  EMEA/H/C/004917
• 16Dec2019

  Rinvoq

  Active substance: upadacitinib

  EMEA/H/C/004760
• 8Jan2018

  Fasenra

  Active substance: Benralizumab

  EMEA/H/C/004433
• 8Jan2018

  Jorveza

  Active substance: budesonide

  EMEA/H/C/004655
• 26Sep2017

  Dupixent

  Active substance: dupilumab

  EMEA/H/C/004390

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

• Biologics and biosimilars
• Skin and hair
• Respiratory
• Immune health
• Gut health